Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood
NCT00047268Phase 3Unknown
- Sponsor
- European Working Group of MDS in Childhood
- Start
- Jul 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cytarabine and mercaptopurine in myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) (6 arms), sponsored by European Working Group of MDS in Childhood. Primary endpoint: Patient numbers in the different FAB subtypes. Status: unknown.
02
Drugs
cytarabinemercaptopurine
03
Conditions
myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT00047268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00047268.